-
Study of Two Dose Regimens of Ticagrelor Compared with Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention for Stable Coronary Artery Disease (STEEL-PCI)Orme RC, Parker WAE, Storey RF et al. -
Higher neutrophil-to-lymphocyte ratio (NLR) increases the risk of suboptimal platelet inhibition and major cardiovascular ischemic events among ACS patients receiving dual antiplatelet therapy with ticagrelorM Verdoiaab, M Nardinb, R Gioscia et al.
-
Extended antiplatelet therapy with clopidogrel alone versus clopidogrel plus aspirin after completion of 9- to 12-month dual antiplatelet therapy for acute coronary syndrome patients with both high bleeding and ischemic risk. Rationale and design of the OPT-BIRISK double-blinded, placebo-controlled randomized trialYi Li, QM Jing, YL Han et al.
-
Dual Antiplatelet Therapy Duration in Medically Managed Acute Coronary Syndrome Patients: Sub-Analysis of the OPT-CAD StudySicong Ma, Zaixin Jiang, YL Han et al.
-
Genotyping to Guide Clopidogrel Treatment: An In-Depth Analysis of the TAILOR-PCI TrialNaveen L. Pereira, MBBS, FACC
-
6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trialHahn JY, Song YB, SMART-DATE investigators et al.
-
1-Year Outcomes of Delayed Versus Immediate Intervention in Patients With Transient ST-Segment Elevation Myocardial InfarctionGN Janssens, NW van der Hoeven, JS Lemkes et al.
-
Conceptual Framework for Addressing Residual Atherosclerotic Cardiovascular Disease Risk in the Era of Precision MedicinePatel KV, Pandey A, de Lemos JA et al.
http://www.cbsmd.cn Contact us by cbs@cbsmd.cn
Copyright ⓒ CBSMD Nanjing China. All rights reserved.
